CHU Montpellier, Av G Giraud, 34295 Montpellier, France.
Regen Med. 2011 Nov;6(6 Suppl):44-51. doi: 10.2217/rme.11.80.
Multipotent mesenchymal stromal cells or mesenchymal stem cells (MSCs) are mainly isolated from bone marrow or fat tissue. Owing to their potential for multilineage differentiation towards bone, cartilage and fat tissue, they were initially evaluated in innovative strategies for tissue engineering. More recently, they have gained interest for their immunomodulatory properties and have been tested in various clinical trials that aim to modulate the host immune response in graft-versus-host disease or autoimmune diseases. MSC-mediated immunomodulation occurs through the secretion of soluble mediators. The clinical applications of MSCs for rheumatic diseases focus on their potential to promote tissue repair/regeneration and prevent inflammation. This article will focus on the mechanisms by which MSCs might exhibit a therapeutic potential in rheumatology. Special attention is given to their potential for innovative future strategies.
多能间充质基质细胞或间充质干细胞（MSCs）主要从骨髓或脂肪组织中分离得到。由于它们具有向骨、软骨和脂肪组织多谱系分化的潜力，最初被评估用于组织工程的创新策略。最近，由于其免疫调节特性，它们已在各种临床试验中得到测试，旨在调节移植物抗宿主病或自身免疫性疾病中的宿主免疫反应。MSC 介导的免疫调节是通过可溶性介质的分泌来实现的。MSCs 在风湿性疾病中的临床应用集中在它们促进组织修复/再生和预防炎症的潜力上。本文将重点介绍 MSC 在风湿病学中可能表现出治疗潜力的机制。特别关注它们在创新未来策略中的潜力。
